Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm
NCT04358562Phase 2Unknown
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Nanchang University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04358562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358562.